答：根据近期市场行情，VC 产品价格整体保持稳定。产品价格 受原材料成本、市场供需关系、行业库存等多重因素综合影响，具 有不确定性。从目前来看，下游需求端保持增长。公司对二季度的 市场展望持谨慎乐观态度，并将继续通过精益管理控制成本，提升 产品竞争力。具体的价格走势受宏观环境影响较大，敬请投资者注 意投资风险。 4. 主营业务原料药及中间体、微生物蛋白今年的经营目标？ 江西富祥药业股份有限公司 投资者关系活动记录表 | 证券代码：300497 | 编号：20260302 | 证券简称：富祥药业 | | --- | --- | --- | | | □ 特定对象调研 □ 分析师会议 | | | 投资者关系活动 | 媒体采访 业绩说明会 □ □ | | | 类别 | 新闻发布会 路演活动 □ √ | | | | 现场参观 其他 □ □ | | | 参与单位名称及 | 国金证券、中金基金、博时基金、摩根基金、中航基金、东方基金、 | | | 人员姓名 | 华福资管、中哲物产、中加基金、紫金信托、湖南长心私募、德邦 | | | | 基金、交银理财、玄元投资、盘京投资、海富通基金、光大永明资 | | | | 产、上海信托 ...

2月26日，"2026年常州—上海经贸交流和创新合作活动周"客商新春交流会在上海举行。这是常州连续第20年在上海举办经贸交流活动。从产业创新到 区域协同，从经贸交流到人文交融，"沪联互通、常来常往"已成为长三角一体化背景下沪常合作共赢的生动注脚。 本次活动周期间，预计达成合作项目28个，投资总额超过194亿元。 王剑锋表示，常州将全面融入全国统一大市场建设，全力营造市场化、法治化、国际化一流营商环境，让每一个项目都能在常州投资安心、发展顺心。 诚挚欢迎更多上海企业和人才选择常州、深耕常州，共同书写长三角一体化发展新篇章。 常州市委书记王剑锋在致辞中表示，上海是改革开放前沿阵地、高质量发展标杆示范，"五个中心"建设动能强劲，持续引领长三角迈向世界级城市群。 常州作为长三角重要中心城市，近年来全方位服务和融入上海大都市圈，经济社会保持稳中有进、向新向优发展态势。 常州宣传部供图 2025年，常州实现地区生产总值近1.12万亿元、增长5.2%；一般公共预算收入715.5亿元，税收占比85.5%，高于全省平均8个百分点、居全省第一；工 业规模超2.2万亿元、全省第三，新能源产业开票突破万亿元，产业底座更加稳固。 面向 ...

走进实验室，整齐排列的一个个生物反应器，就是一座座"无声工厂"，肉眼不可见的微生物作为"新型 工人"，一呼一吸之间就能生产各类合成生物产品，堪称"生物造万物"。刘波介绍，最近，"新型工 人"的研发也在持续进行，公司菌种库内保存的微生物样本已达十余万种，随着研发的推进，这个数字 仍在不断增长。 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 本报讯（记者 刘苏雅）春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内， 一批微生物"工人"已经开工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产 ...

Core Insights - The article discusses the unpredictable nature of the market and the importance of adaptability for entrepreneurs, especially during economic fluctuations [4][6]. - It emphasizes the significance of long-term strategies over short-term gains in entrepreneurship, highlighting the need for resilience and careful decision-making [8][11]. Financing and Market Conditions - The article reflects on the current state of financing, indicating a warming market compared to previous years, with a focus on how entrepreneurs navigated through capital winters [6][10]. - It mentions that many entrepreneurs faced significant challenges during the capital winter, including budget overruns and delays in project delivery, which led to critical adjustments in their business strategies [9][10]. Entrepreneurial Experiences - Entrepreneurs shared their experiences of overcoming financial difficulties, including instances where they had to halt projects due to cash flow issues and the importance of maintaining team morale during tough times [10][11]. - The article highlights the shift in focus for some companies from ambitious expansion plans to more sustainable, focused product development in response to market conditions [17][18]. Industry Trends and Future Outlook - The article notes that the synthetic biology and AI sectors are gaining traction, with significant potential for growth as they align with national policies and market demands [12][21]. - It discusses the increasing interest from investors in sectors like biotechnology and industrial automation, indicating a shift in funding dynamics and a growing recognition of the long-term value of these industries [52][53]. Strategic Partnerships and Collaborations - The importance of strategic partnerships is emphasized, with examples of companies successfully collaborating with larger firms to enhance their operational capabilities and market reach [10][27]. - The article also mentions how companies are leveraging government support and resources to navigate challenging market conditions and secure funding [52][55].

瑞丰高材（300243.SZ）2月13日在投资者互动平台表示，公司子公司瑞丰生物主要从事合成生物材料的 开发，在聚乳酸、丁二酸、右旋糖酐等产品领域有一定的技术积累。其中，右旋糖酐已正常对外销售， 正进一步积极开拓市场，下游用于制备动物补铁剂右旋糖酐铁。2026年，公司将进一步扩大右旋糖酐的 产能，并进一步开拓销售市场。公司将以全资子公司瑞丰生物为主体，继续通过自研、与成熟技术成果 开展合作等方式丰富合成生物产品的品类。努力做强做大公司合成生物材料业务。公司合成生物相关产 品业务尚处于起步阶段，短期内不会对公司业绩产生较大影响，敬请广大投资者注意投资风险。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司对生物制造的长期发展规划是什么？未来如何实 现规模化发展？ ...

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...

另外，莱茵生物经过二十余年的深耕积淀，所形成的综合优势及行业地位，相信也是德福资本综合考量 的关键因素。一是产业布局完善、体系健全，公司拥有充足的产能储备、领先的生产技术、完善的QA 及QC质量管控体系、规范的治理结构，以及覆盖全球的销售网络，企业发展底盘坚实牢靠；二是公司 具备系统的选品、拓品与产品孵化能力， 这种能力依托于公司完整的研发、开发、产业化全链条布局，能够实现产品从概念到落地的高效转化； 三是具备业务持续升级的内驱力与技术迭代能力，公司始终保持敏锐的技术前瞻意识，近年来主动布局 合成生物、配方应用等前沿领域，并成功实现了技术的迭代升级，同时紧跟行业发展趋势，积极开拓动 物饲料、宠物营养等多元应用场景，体现了公司较好的发展活力与成长潜力。此次德福资本选择与莱茵 生物合作，既是对公司业务发展的高度认可，也彰显了对公司未来前景的坚定信心。 答：首先在战略层面，德福资本与莱茵生物都高度看好天然健康成分这一细分赛道，且德福资本对莱茵 生物的发展战略予以高度认可。双方在战略层面高度契合、理念一致，这是此次合作达成的基础前提， 也是核心驱动力之一。 格隆汇2月11日丨莱茵生物(002166.SZ)在投资者关系 ...

Group 1: Transaction Overview - The transaction with Defo Capital involves the transfer of 8.09% equity from the original controlling shareholder and the acquisition of 95.5% equity in Beijing Jinkangpu, aimed at vertical integration in the industry [3][4] - The acquisition is expected to enhance the company's capabilities in customer service, channel diversification, and resource integration, providing strong support for future development [2][3] Group 2: Strategic Alignment - Defo Capital's focus on the health sector aligns with the company's strategic direction, recognizing the potential in natural health components [4][5] - The company has over 20 years of industry experience, a robust production capacity, and a comprehensive quality control system, making it an attractive partner for Defo Capital [5][6] Group 3: Business Development Plans - The company plans to focus on two main directions for its synthetic biology business: developing proprietary products and providing industrialization services for external clients [6][7] - The RM2 product, a key natural sweetener, is expected to reshape the market, with plans for promotion through high-quality product and formulation services [7][8] Group 4: Capacity and Utilization - The company has established multiple extraction facilities, ensuring sufficient capacity, but current utilization rates are low due to new facilities not yet being operational [8][9] - Future capacity release will depend on sales growth of core products and the introduction of new synthetic biology products into the market [9][10] Group 5: Global Operations - The upgrade of the U.S. extraction facility aims to enhance supply chain security and meet global customer demands, focusing on producing raw materials advantageous in North America [9][10] - The company plans to optimize overseas capacity and improve product delivery efficiency to achieve significant operational improvements in the U.S. market [9]

Core Insights - The article emphasizes the transformative role of synthetic biology in reshaping the chemical industry towards a green and low-carbon future, with Anhui Huaheng Biotechnology Co., Ltd. as a leading player in this change [1][2]. Group 1: Company Leadership and Strategy - Guo Henghua, the chairman and general manager of Huaheng Biotechnology, has successfully positioned the company as a leader in the amino acids and bio-based products sector through keen market insights and technical expertise [1]. - The company adopts an "engineering mindset" throughout the product development and industrialization process, ensuring a seamless transition from laboratory breakthroughs to market-ready products [1][2]. Group 2: Technological Advancements and Industrialization - After initial technological breakthroughs in amino acids, the company focused on pilot testing and scaling up to address critical issues such as stability, batch consistency, and cost control, leading to long-term stable operation of industrial facilities [2]. - The research team enhances production efficiency and yield by optimizing fermentation processes and purification methods, ensuring a stable market supply of bio-based materials and functional raw materials [2]. Group 3: Global Market Position and Collaboration - Under Guo Henghua's long-term strategic vision, Huaheng Biotechnology maintains a leading position in the global market and continues to expand its core role in the international supply chain [2]. - The company has established partnerships with multiple international firms, broadening its overseas market presence and solidifying its position within the global bio-manufacturing industry [2]. Group 4: Future Outlook - As synthetic biology technology continues to evolve, the company aims to explore pathways for high-quality development in China's bio-manufacturing sector and contribute to the high-quality growth of the chemical economy [3].

Core Insights - The company has grown from 3 to over 400 employees, supported by comprehensive policies from Changping District, including 32 targeted support measures and an investment of 80 million yuan from a municipal health fund [1][2] - Changping District aims to establish itself as a leading hub for synthetic biology manufacturing, with a focus on high-quality industrial development [1][2] Group 1: Company Growth and Support - The company has completed nearly 300 million yuan in a new round of equity financing to accelerate the development of methanol-based bio-manufacturing products [1] - Changping District has established 146 synthetic biology manufacturing enterprises and 16 common technology service platforms, with over 300 million yuan in registered capital [2] - The district has received national recognition as the first national characteristic industrial cluster in synthetic biology manufacturing [2] Group 2: Innovation and Talent Development - Changping has formed a strategic industry fund of 1 billion yuan to connect various stakeholders in the "government-industry-university-research-application" ecosystem [3] - Notable achievements include the selection of a bio-synthetic product for a major technology forum and advancements in addressing critical technology challenges [3] - The company has received approval for the production of several products, including new yeast proteins and alose sugar, with multiple products accelerating through the approval process [3] Group 3: Future Plans and Objectives - The future city group aims to incubate 10 landmark projects by 2026, enhancing the innovation center's influence and optimizing the industrial ecosystem [4] - The group has facilitated over 90 project connections and aims to secure 3 billion yuan in intended credit from financial institutions [4] - Plans include establishing a pilot base for synthetic biology manufacturing to address challenges in technology transfer [4]